（原标题：科伦药业：控股子公司抗PD-L1塔戈利单抗获批上市） 证券时报e公司讯，科伦药业(002422)1月1日晚间公告，公司控股子公司四川科伦博泰生物医药股份有限公司用于治疗既往接受过2线及以上化疗失败的复发或转移性鼻咽癌患者的靶向程序性细胞死亡配体1(PD-L1)的创新人源化单克隆抗体(简称“单抗”)塔戈利单抗(前称KL-A167)(科泰莱®)已获国家药监局批准于中国上市。

Envafolimab is under clinical development by Alphamab Oncology and currently in Phase I for Non-Small Cell Lung Cancer.

Envafolimab is under clinical development by Alphamab Oncology and currently in Phase I for Metastatic Breast Cancer.

High levels of immune infiltrates are strongly prognostic for favorable outcomes independently of nodal status in ...

The decision follows a similar one in the US and is due to the drug's failure to significantly improve overall survival versus chemo in the TROPION-Lung01 trial.

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. 2. In ...

Tevimbra is already approved in the US for the treatment of unresectable or metastatic oesophageal squamous cell carcinoma ...

Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...

INR:7527. live mpl score FDA grants Fast Track designation to Assembly's second-generation core inhibitor ABI-H2158 Pfizer invests $200 million in CStone Pharmaceu ...

Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE) of the National ...

INR:0738. play microgaming slots R&D Daily: AstraZeneca's PD-L1 inhibitor receives priority review, reducing the number of treatments by half Phase 3 clini ...